Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.50 |
| ▸ | PPARD | Q03181 | 6/20 | 0.50 |
| ▸ | PPARA | Q07869 | 6/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.48 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | ADA | P00813 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979614 | 0.91 | MCL1 (0.51) | PPARGPPARDPPARAMCL1PLA2G4A | |
| SCHEMBL29138523 | 0.85 | MTNR1A (0.56) | MAPTKMT2A | |
| SCHEMBL4478676 | 0.81 | PPARD (0.56) | PPARGPPARDPPARAMCL1KMT2A | |
| SCHEMBL30395677 | 0.81 | PPARD (0.56) | PPARGPPARDPPARAMCL1KMT2A | |
| SCHEMBL4467932 | 0.81 | PPARG (0.45) | PPARGPPARDPPARAMCL1PLA2G4A | |
| SCHEMBL4468257 | 0.80 | CA12 (0.48) | PPARGPPARDPPARAMCL1PLA2G4A | |
| SCHEMBL30396580 | 0.78 | F2 (0.45) | MAPTKMT2A | |
| SCHEMBL3689068 | 0.78 | F2 (0.45) | MAPTKMT2A | |
| SCHEMBL3873618 | 0.78 | PPARG (0.44) | PPARGPPARDPPARAMCL1PLA2G4A | |
| SCHEMBL2006435 | 0.78 | MCL1 (0.45) | PPARGPPARDPPARAMCL1PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| US-20060166983-A1 | Indole derivatives as ppar modulators | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166983-A1 | Indole derivatives as ppar modulators | PPARA, PPARD, PPARG | PPARG 3/4885PPARD 2/4885PPARA 1/4885 |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | PPARG 1/4885PPARD 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.